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Objective. To define a minimum Standard Set of outcome measures and case-mix factors for monitoring, comparing, and
improving health care for patients with clinically diagnosed hip or knee osteoarthritis (OA), with a focus on defining the
outcomes thatmattermost to patients.
Methods. An international working group of patients, arthroplasty register experts, orthopedic surgeons, primary care
physicians, rheumatologists, and physiotherapists representing 10 countries was assembled to review existing literature and
practices for assessing outcomes of pharmacologic and nonpharmacologic OA therapies, including surgery. A series of 8
teleconferences, incorporating amodifiedDelphi process, were held to reach consensus.
Results. The working group reached consensus on a concise set of outcome measures to evaluate patients’ joint pain,
physical functioning, health-related quality of life, work status, mortality, reoperations, readmissions, and overall sat-
isfaction with treatment result. To support analysis of these outcome measures, pertinent baseline characteristics and
risk factor metrics were defined. Annual outcome measurement is recommended for all patients.
Conclusion. We have defined a Standard Set of outcome measures for monitoring the care of people with clinically diag-
nosed hip or kneeOA that is appropriate for use across all treatment and care settings.We believe this Standard Set provides
meaningful, comparable, and easy to interpret measures ready to implement in clinics and/or registries globally. We view
this set as an initial step that, when combined with cost data, will facilitate value-based health care improvements in the
treatment of hip and kneeOA.
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INTRODUCTION
Total expenditures on health care as a percentage of the gross
domestic product continue to rise worldwide (1). Yet the
World Health Organization estimates that 20–40% of health
care costs are unnecessary (2). Uncertainty about health out-
comes combined with increasing costs has driven interest in
value-based health care (i.e., the idea of competition on value
rather than volume in health care), where value is defined as
the ratio between patient outcomes and the costs necessary
to achieve those outcomes. By focusing on the measurement
and reporting of outcomes that matter to patients over the
full cycle of care, value-based health care empowers patients
to make informed choices about their care and enables pro-
viders to improve outcomes, increase efficiency, streamline
care processes, and decrease the costly and inefficient frag-
mentation of care delivery (3). Currently, a major challenge
in measuring value in health care is the lack of universal
metrics for defining value. Therefore, in an effort to facilitate
the transition to value-based health care, the International
Consortium for Health Outcomes Measurement (ICHOM)
convenes international working groups to develop standard-
ized and concise outcome measure sets for specific medical
conditions, with a focus on the outcomes that matter most to
patients (www.ichom.org).
Hip and knee osteoarthritis (OA) are among the leading cau-
ses of global disability, with an aging and increasingly obese
population worldwide likely to increase its prevalence (4).
The total annual cost of OA per patient has been estimated to
be as much as $5,700 in the US (5). Pain and impaired joint
function are the main limiting symptoms affecting patients
with OA, which typically develops over the course of many
years, with varying symptom intensity over time (6). The mod-
ern management of symptomatic hip or knee OA involves
holistic assessment and selection of therapies from a wide
range of options, ranging from lifestyle interventions and edu-
cation to oral medication and joint replacement surgery (7).
All patients should be offered basic treatment options such as
lifestyle interventions and education (8). Many patients will
require options such as physiotherapy, walking aids, oral
medication, or intraarticular injections. If nonsurgical treat-
ment alternatives are insufficient to control symptoms, a
smaller group of patients may be candidates for joint replace-
ment or other surgical interventions.
The field of orthopedics is a leader in the measurement
of outcomes and use of patient-reported outcome measures
(PROMs). Joint replacement registries have demonstrated
how routine measurement of outcomes can improve clini-
cal practice by eliminating low-value treatments or harm-
ful implant devices (9,10). However, most joint registries
focus on postmarket surveillance of implants rather than
patient-reported satisfaction and function. Moreover, joint
replacement represents only a fraction of all care associated
with hip and knee OA.
Previous efforts at defining universal standards for
measuring hip and knee OA outcomes have focused on
assessment of physical functioning and metrics for use in
clinical trials (11,12). However, there is no common defi-
nition of key outcome measures for use in clinical care
across all treatments for this condition. The objective of
this work was to define a minimum Standard Set of
outcome measures and case-mix factors for evaluating,
comparing, and improving the clinical care of patients
with hip or knee OA, with a focus on the outcomes that
matter most to patients.
MATERIALS AND METHODS
Working group assembly and composition. This work
was initiated by ICHOM, a nonprofit organization focused on
the development and international adoption of standardized
outcome measures for major medical conditions. ICHOM
convened a working group composed of 2 patient representa-
tives and 21 international experts in various fields of OA care
Significance & Innovations
 The work presented here expands upon current
regional and national registry efforts from around
the globe and represents the first internationally
developed core outcome set for the evaluation and
comparison of the treatment of hip or knee osteoar-
thritis (OA) in clinical practice across providers,
regions, and countries.
 This work also expands upon current registry efforts
by providing a single set of outcome measures to
evaluate the full continuum of care for hip and knee
OA, from self-managed and symptomatic treatment
to total joint replacement surgery.
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and research. The working group provided balanced repre-
sentation across geographic locations, medical specialties,
and existing joint replacement registries and international
initiatives as shown in Supplementary Appendix A (avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22868/abstract). The
activities of the working group were coordinated by a project
team consisting of a working group lead (PDF), 2 project
leaders (LvM and SW), a research fellow (OR), and the
ICHOM Vice President of Research and Development (CS).
Work process and decision-making. The Standard Set
was developed using a modified Delphi process (13). Between
July 2014 and March 2015, 8 teleconferences were held by
the working group. Each teleconference had a specific goal,
such as establishing the scope of the Standard Set, defining
the patient population, selecting the appropriate outcomes
and case-mix domains, and defining the relevant metrics.
For each topic, the project team reviewed the existing litera-
ture and current practices and gathered input from expert
interviews to develop proposals for discussion at the tele-
conference. Detailed minutes of these discussions were dis-
tributed to working group members, who voted on each item
of the project team’s proposal via online survey. Each item
required a 67% majority vote of survey respondents to be
included in the Standard Set. Survey items with less than
67% majority were either excluded from the Standard Set or
revised by the project team and presented again for discus-
sion and voting at the next teleconference.
RESULTS
Response rates and scope. Response rates for the 6 post-
teleconference surveys were 90%, 85%, 71%, 84%, 85%,
and 84%, respectively. Group size fluctuated slightly due to
the late addition of some members and temporary leaves of
absence of others. The working group first defined the
patient population for which outcomes are to be measured.
The diagnosis of hip or knee OA is not always straightfor-
ward. Patients with radiographic signs of OA may not have
any symptoms while others with severe symptoms have no
radiographic changes. Therefore, diagnosis is based on an
overall assessment of risk factors, symptoms, and clinical
examination (14). There are a variety of treatment options
available to meet patients’ needs, depending on the severity
of symptoms and stages of disease. Due to this complexity,
we decided that the Standard Set should target all patients
with clinically diagnosed, symptomatic OA of the hip or
knee, regardless of treatment. There was unanimous agree-
ment with this scope within the working group.
Outcome domains and measures. Hip and knee pain,
hip and knee function, health-related quality of life (HRQOL),
and work status formed the core outcome domains, reflecting
the main limiting symptoms of hip and knee OA. Table 1
shows all outcome domains and measures included in the
Standard Set and the percentage of working group members
who agreed with their inclusion. The selection of measures to
capture the outcome domains above was based on an assess-
ment of the domain coverage, psychometric properties, feasi-
bility to implement, and clinical interpretability of available
measures. We aimed to balance pragmatism with comprehen-
siveness by selecting instruments that adequately capture the
relevant domains in a parsimonious manner.
Hip- and knee-specific PROMs. A variety of PROMs
instruments for evaluating hip and knee function exist. The
24-item Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) assesses pain, disability, and joint stiff-
ness in patients with hip and knee OA (15) and has proven
valid, reliable, and responsive to OA outcomes (15,16).
However, in addition to being lengthy, it requires a licensing
fee to use, potentially limiting broad implementation. The
12-item Oxford Knee and Hip Scores assess pain and func-
tion and were designed to measure outcomes following joint
replacement surgery (17,18). They are widely used in clini-
cal studies and joint replacement registries, but how appli-
cable they are to the general OA population is unclear, and
they require a license for use. Developed as extensions of
the WOMAC, the Knee Injury and Osteoarthritis Outcome
Score (KOOS) and the Hip Disability and Osteoarthritis Out-
come Score (HOOS) are nonproprietary comprehensive
alternatives (19,20). However, these questionnaires are long
(42 and 40 items, respectively), representing a burden to the
respondent. Fortunately, short versions (the KOOS-PS
and HOOS-PS) have been developed, consisting of 7 and 5
questions, respectively. Despite their brevity, these instru-
ments exhibit good measurement properties in the domain
of physical functioning and are free of charge to use. The
KOOS-PS has been translated into 15 languages, including
the 4 most widely spoken, and the HOOS-PS has 10
translations. Following careful consideration, the working
group agreed to recommend use of the KOOS-PS and
HOOS-PS as measures of hip and knee function in the Stan-
dard Set (21,22).
The HOOS-PS and KOOS-PS do not include a measure of
pain. It is common to assess pain using visual analog scales
(VAS) or numeric rating scales (NRS). Despite their differ-
ences in granularity, possible modes of collection, and
presentation requirements, these instruments provide con-
gruent results (23). Therefore, to facilitate implementation
and align with current practices, the working group agreed to
recommend assessment of joint pain via either VAS or NRS
(11-item version) using a 1-week recall period (19,20). Given
the prevalence of multijoint OA, the group also agreed that
pain would be assessed for all 4 relevant joints (i.e., the right
hip, left hip, right knee, and left knee) as well as the lumbar
spine.
HRQOL PROMs. There are several tools available to
measure HRQOL in patients with hip or knee OA. However,
existing practices and the volume of supporting research
narrow the options to 2 main alternatives: the Short Form
health surveys (available at www.sf-36.org) and the EuroQol
health outcome measures (available at www.euroqol.org).
The Short Form 36 health survey (SF-36) assesses 8 dimen-
sions of health, which can be summarized into a physical
health and mental health composite score (24). As the most
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commonly used generic PROM in clinical trials, the SF-36
has proven to be a psychometrically sound tool for patients
with OA (25). However, the shortened version, SF-12, is pre-
ferred for routine followup in joint replacement registries
for practicality of data collection (26).
The EuroQol 5-domain instrument (EQ-5D) is a generic
measure of health status developed by the EuroQol Group (27).
It consists of questions assessing 5 health outcome domains,
which can be summarized into a single score, and a VAS
assessing current overall health state. Although alternative
versions exist, the original EQ-5D with 3 levels of response
options is by far the most commonly used and best validated
in OA patients (28).
Whereas the EuroQol and SF tools require the purchase of
a license, an equivalent Veterans SF-12 (VR-12), is freely
available for noncommercial use (29). Considering the wide-
spread use of both EQ-5D and SF-12/VR-12 in existing
orthopedic registries and the absence of major advantages of
one over the other, the working group agreed to recommend
use of either tool for HRQOL evaluation. For comparisons, a
cross-walk algorithm is available to convert SF-12 responses
into an EQ-5D index score (30).
Work status. The standard ICHOM question for evaluat-
ing work status was recommended (31). The exact question
and response options are shown in Table 1. Comparing
responses to this question at baseline and regular followup
intervals will reveal the impact of OA on a patient’s ability
to work over time.
Satisfaction. In addition to measuring health status
directly, there are other useful patient-reported measures
of treatment success, such as satisfaction, fulfillment of
expectations, and willingness to repeat or to recommend
treatment to others. Although such measures are not true
PROMs, they are clearly associated with changes in PROM
scores and may indicate how well a provider manages to
engage the patient in shared decision-making and to set real-
istic expectations on outcomes (32). As nonsurgical and sur-
gical treatments differ in their effectiveness and risk profiles,
Table 1. Outcome domains and definitions included in the Standard Set*
Category and outcome domain Outcome definition Agreement†
Patient-reported health status
Hip and/or knee function Tracked via HOOS-PS or KOOS-PS 100
Pain in hips, knees,
or lower back
Tracked via numeric or visual analog rating scales 88
Quality of life Tracked via EQ-5D-3L, SF-12, or VR-12 100
Work status What is your work status? Unable to work due to a condition other than
osteoarthritis; unable to work due to osteoarthritis; not working by choice
(student, retired, homemaker); seeking employment (I consider myself able to
work but cannot find a job); working part-time; working full-time
77
Satisfaction with results How satisfied are you with the results of your treatment? Very satisfied; satisfied;
neither satisfied nor dissatisfied; unsatisfied; very unsatisfied
88
Surgical outcomes
Death All-cause 30-day mortality 100
Admissions All-cause 30-day readmissions 88
Reoperation Any consecutive open surgery performed on the hip or knee. Includes both minor
and major reoperations. Minor revision: any reoperation with removal, exchange,
and/or addition of minor implant part (e.g., head, liner). Major revision: any
reoperation with removal, exchange, and/or addition of major implant part (e.g.,
cup, femoral component, tibial component)
94
Disease progression
Treatment progression Which of the following treatments have you undergone in the past year for your
osteoarthritis related hip or knee problems? (Tick all that apply) Information/
advice (ex: patient education, advice on diet, exercise, or other lifestyle
alterations); self-managed care (ex: nonprescription oral pain medication,
medications applied to the skin, exercise, or diet program); nonsurgical, clinical
care (ex: nonsteroidal antiinflammatory drugs or other prescription drugs,
supervised physical or occupational therapy, orthosis or other ambulatory aids,
injections directly into the joint); surgery (ex: osteotomy, resurfacing, partial or
total joint replacement)
82
Care utilization In the past year, which of the following health care providers have you seen for
treatment of your osteoarthritis-related hip or knee problems? (Tick all that
apply) Health educator/peer support group, dietician, physical therapist, or
general practitioner; rheumatologist; orthopedic surgeon; alternative health
practitioner
82
* HOOS-PS5Hip Disability and Osteoarthritis Outcome Score short version; KOOS-PS5Knee Injury and Osteoarthritis Outcome Score short
version; EQ-5D-3L5EuroQol 5-domain instrument with 3 levels; SF-125Short Form 12 health survey; VR-125Veterans Short Form 12 health
survey; ex5 example.
† Percentage agreement among survey respondents.
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the working group agreed on overall satisfaction with treat-
ment results as a common outcome domain for evaluating all
treatments (33).
Complications and adverse events. The working group
considered different approaches for measuring com-
plications and adverse events of surgical treatments. In
the absence of uniform, internationally applicable defini-
tions for such events, the working group recommended
the commonly used all-cause 30-day readmission and all-
cause 30-day mortality following surgical intervention
(34). In addition, any complication requiring return to the-
ater for a consecutive surgery (whether major or minor
and regardless of when it occurred) was considered a
reoperation and must be recorded. Due to the diversity of
nonsurgical OA treatments and the lack of specificity of
potential complications, we did not consider it feasible to
measure complications and adverse events associated
with nonsurgical care in this Standard Set.
Disease progression measures. As the natural course of
OA is chronic and progressive, the working group felt that it
was important to include measures that indicate disease pro-
gression and developed 2 questions to capture this outcome
(Table 1). These questions ask which treatments the patient
has undergone and which care providers the patient has con-
sulted for their hip or knee problems in the past year. Annual
measurement will reveal intensifications of treatment, indi-
cating disease progression. The validity and utility of these
questions will be evaluated following the collection of pilot
data, and necessary changes will be made.
Case-mix factors. A number of patient characteristics
and risk factors are known to influence the outcomes shown
in Table 1. To ensure fair comparisons across providers with
diverse patient populations, the working group identified
and defined key adjustment measures to include in the Stan-
dard Set. We sought internationally valid measures that
minimized the burden of data collection on both patients
and health care providers. As described above for the selec-
tion of outcome measures, the working group first agreed on
the risk factor domains to be included and then selected def-
initions for measuring these domains. Selected domains
were patient demographics, body habitus, lifestyle factors,
Table 2. Case-mix variable domains and definitions included in the Standard Set
Category and case-mix
factor domain Case-mix factor definition Agreement*
Demographics
Age Date of birth 100
Sex Sex at birth 100
Education level Please indicate the highest level of schooling completed: none, primary,
secondary, tertiary (university or equivalent)
88
Baseline clinical status
Joint-specific history Please indicate if the patient has a history or findings of any of the following for
each hip and knee: none; trauma or ligmental injury; congenital or
developmental disorders; other joint disorders including but not limited to
osteonecrosis, inflammatory arthritis, gouty arthritis, septic arthritis, and
Paget’s disease of the bone
84
Joint-specific
surgical history
Please indicate the type of surgery the patient has on each hip and knee: none;
joint replacement; osteotomy; osteosynthesis/facture surgery; ligament
reconstruction (knee only); other arthroscopic procedures
82
Other case-mix factors
Living status Which statement best describes your living arrangement? I live with partner/
spouse/family/friends; I live alone; I live in a nursing home/hospital/other
long-term care home; other
100
Body mass index Calculated from patient-reported height and weight 88
Physical activity In a typical week, how much time do you spend doing physical activity?
Physical activity is any activity that makes you breathe hard, feel warm, and
feel your heart beat faster. Examples of physical activity are walking,
bicycling, and dancing and also housecleaning and gardening. None; about
30 minutes; about 1 hour; about 2 hours; more than 2 hours
88
Tobacco smoking status Do you smoke? No/yes 88
Comorbid conditions Have you been told by a doctor that you have any of the following? (Tick all
that apply to you) Heart disease (for example angina, heart attack, or heart
failure); high blood pressure; problems caused by a stroke; leg pain when
walking due to poor circulation; lung disease (for example asthma, chronic
bronchitis, or emphysema); diabetes mellitus; kidney disease; diseases of the
nervous system (for example Parkinson’s disease or multiple sclerosis); liver
disease; cancer (within the last 5 years); depression; arthritis in your back or
other condition affecting your spine; rheumatoid arthritis or another kind of
arthritis in addition to osteoarthritis
92
* Percentage agreement among survey respondents.
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joint related factors, and comorbidities. Table 2 shows
a complete list of the risk adjustment measures with the
percentage of working group members who agreed on their
inclusion.
Demographics, body habitus, and lifestyle factors. The
key demographic factors considered important to include
in the Standard Set were patient age, sex, and socioeco-
nomic status (35–37). Although many different indicators
of socioeconomic status have been published in the litera-
ture, only education level as defined by the International
Standard Classification of Education can be considered con-
sistent across countries and cultures for international use
(36,38). The working group also identified body mass index,
smoking status, and living condition as having a potentially
important influence on outcomes and relevant for inclusion
in the Standard Set (39).
Although physical activity was considered an important
factor affecting treatment outcomes, an appropriate and fea-
sible measure could not be identified. Therefore, the work-
ing group adapted a question from the Better Management of
Patients with Osteoarthritis Registry in Sweden to create the
question shown in Table 2. The working group recommends
but does not require the use of this newly developed ques-
tion. The validity of this question will be tested and its for-
mal inclusion in the Standard Set determined in time.
Joint history. The diversity of symptoms and clinical
presentations of OA as well as its multifactorial etiology sug-
gest that OA is a heterogeneous group of disorders with a
common structural end point (40). Unfortunately, despite a
large body of research, there is no commonly accepted sys-
tem for classifying OA phenotypes (41). As specific disease
history and etiology may influence disease progression and
outcome of treatment, in the absence of an existing, robust
classification system, the working group developed a simple
physician-reported measure of joint history that broadly
categorizes OA etiologies (Table 2). A similar physician-
reported measure of joint-specific previous surgical history
was also included in the set. Physicians are asked to report
these measures for all 4 joints, as multiple joint involvement
affects outcomes (42).
Comorbidity status. Comorbidities are known to affect
outcomes following joint replacement surgery (43). Although
there is limited research on the effects of comorbidities on
nonsurgical OA treatments, they likely also affect these out-
comes and, in some cases, the available treatment options.
Therefore, there was strong consensus within the working
group on the importance of including a measure of comor-
bidities, regardless of treatment modality.
Although well-established systems for classifying comor-
bidity status from clinical or administrative data exist, these
systems were not considered feasible for inclusion in the
Standard Set due to wide variation in how such information
is recorded across countries and health care systems. A 13-
item patient-reported comorbidity index has proven feasible
and useful for risk stratification in the UK’s National Health
Service (NHS) audit for joint replacements (44). It is a simpli-
fied version of the Self-Administered Comorbidity Question-
naire developed by Katz et al, which has been shown to have
strong correlation with measures derived from administra-
tive data (45,46). The index used by the NHS was modified
for inclusion in the Standard Set to include a measure of
spinal disease and inflammatory arthritis (47). Finally, PROMs
measured at baseline provide relevant information about
patients’ baseline wellbeing and may also be used in risk strati-
fication. For example, the working group recommends using
the emotional health components of the SF-12, VR-12, or EQ-
5D to adjust for baseline mental health status.
Data collection timeline. The Standard Set includes a
recommendation for the timing of data collection, which is
shown in Figure 1. Outcomes and case-mix variables were
categorized into baseline and annual measures. All patient-
reported measures are to be collected at baseline and informa-
tion about disease etiology and previous surgeries are col-
lected at baseline via physician report or abstraction from
Figure 1. Data collection timeline.
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clinical records. Annual measures include pain, functional
status, HRQOL, and all nondemographic case-mix variables.
Data collection may begin at diagnosis of OA, at referral
for surgery, or following other major changes in treatment
regime. Presurgery baseline measures may be collected at any
time within a 3-month window preceding the date of surgery.
Once data collection begins, it continues annually for life or
as long as feasible given the constraints of the local health
care system. In the event that a patient has surgery to treat hip
or knee OA after the start of data collection, the data collec-
tion timeline is reset by this event.
Importantly, all annual measures are patient-reported.
This model has been successfully deployed in recent total
joint replacement registry efforts (48–50) and facilitates
implementation by enabling data capture outside the con-
text of clinical care, as data collection may not correspond
with the timing of patient clinic visits. Physician-reported
measures are only required at baseline or prior to surgery,
which correspond to clinic visits.
Although annual measures were considered most appro-
priate for comparing outcomes across providers, the working
group also recognized the value of tracking patient-reported
outcomes in clinical practice to evaluate the effectiveness of
treatments and aid in shared decision-making. Therefore, a
smaller set of optional patient-reported measures (pain and
functional status) are recommended for use in clinical prac-
tice, with the timing of data collection for these measures left
to the care provider’s discretion.
DISCUSSION
The ICHOM working group on hip and knee osteoarthritis
defined a set of patient-centered outcome measures intended
for evaluating the treatment of hip and knee OA and facili-
tating international comparisons, shared learning, and
benchmarking on value across health care systems. The
main outcomes assessed by the Standard Set include joint
pain, physical functioning, HRQOL, work status, mortal-
ity, reoperations, readmissions, and overall satisfaction
with treatment results. In addition, a set of case-mix vari-
ables was defined to enable adjusted comparisons across
different populations, health care providers, or health sys-
tems. Baseline data collection with annual followup is rec-
ommended for comparing outcomes across providers. An
optional set of measures is recommended but not required
for use in clinical practice.
This set of measures focuses on patients with hip or knee
OA, regardless of disease severity, treatment, or type of
provider. In doing so, it enables continuous assessment over
the entire course of the disease in alignment with the funda-
mental framework of value-based health care delivery (51).
Although this approach may currently present an imple-
mentation challenge, we hope it stimulates providers from
different settings to coordinate their activities around the
patient as opposed to conducting isolated interventions, cre-
ating consistency over the full continuum of care.
Traditionally, joint replacement registries commonly orga-
nize data collection by primary intervention, joint, and later-
ality (each joint subject to a primary intervention yields a
new case). This approach is suitable for implant surveillance
and procedure-related outcomes studies but is inappropriate
for evaluating condition- and patient-centered outcomes in
patients with more than 1 affected joint. Patients with OA
will commonly require symptomatic treatment for more than
1 knee and hip, so that primary treatment outcomes such as
function and work status are affected by the total burden of
the condition. Therefore, adoption of the condition- and
patient-centered approach to outcomes measurement recom-
mended here may require restructuring of current databases
(48). We believe, however, that registries that invest in these
changes will gain richer data sets for optimizing joint replace-
ment outcomes.
The Standard Set is publicly available and was designed
to be implemented in a variety of settings. Individual pro-
vider organizations and registries around the world are
encouraged to implement or align with the Standard Set,
with ICHOM working to facilitate the development of the
infrastructure to share and compare results.
Particularly in countries without a government-run health
system or centralized documentation, patients’ clinical data
may be fragmented across several health records due to
changes in providers or insurers or treatment by multiple
providers (e.g., physiotherapists, surgeons, and primary care
physicians). The working group was cognizant of this issue
when structuring the data collection. For patients receiving
nonsurgical treatment, 90% of the measures included in
the Standard Set are patient-reported. Surgery requires the
collection of 3 additional measures. However, with the excep-
tion of adverse events following surgery, all clinical measures
are captured at baseline or presurgical assessment when
patients are routinely evaluated in the clinic. Furthermore,
all annual followup measures are patient reported. This
procedure allows for direct data collection from patients, alle-
viating the need to track records across providers. We recom-
mend that providers and registries begin collecting these
measures over as much of the care continuum as currently
feasible, with the goal of increasing care coordination and
broadening data collection as the necessary infrastructure
evolves.
We aimed to develop a core set of outcome measures
appropriate for evaluating care across countries and clini-
cal settings. To that end, the working group included rep-
resentatives from 5 continents, 10 countries, and a range
of clinical specialties. A similarly well-balanced steering
committee, comprised of 8 members of the original work-
ing group, has been established to govern the Standard Set
and oversee updates or changes over time.
In conclusion, we believe this Standard Set provides
meaningful, comparable, and easy to interpret measures that
are ready to implement in clinics and/or registries globally.
This single set of case-mix and outcome measures allows
comparisons of outcomes across the full continuum of hip
and knee OA care, facilitating communication across pro-
viders and comparisons across treatment modalities. This
knowledge will incentivize and empower providers to
improve care, as well as allow patients, providers, and payers
to make informed decisions about their health care spending
and treatment options. These are crucial ingredients in a
value-based health care system that will benefit all involved
parties through transparency and well-aligned incentives.
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